Atomwise | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
Atomwise is a preclinical pharma company revolutionizing drug discovery through artificial intelligence. The company has developed...
Atomwise is a preclinical pharma company revolutionizing drug discovery through artificial intelligence. The company has developed AtomNet®, a deep learning technology that enables the discovery of small-molecule drug candidates for challenging disease targets. With over 250 partners globally, Atomwise is focused on advancing its internal pipeline and has raised significant funding to support its mission of delivering better medicines faster.
Website
Headquarters
San Francisco, California
Size
51-200 employees
Industry
Biotechnology Research
Specialities
Machine Learning, Artificial Intelligence, Drug Discovery, Computer Aided Drug Design
🛍️ Atomwise Product and Pricing News →
👔 Atomwise CEO, Management and Leadership Team →
⚔️ Atomwise Alternatives and Competitors →
💼 Atomwise Hiring and Layoffs →
🤖 Atomwise Developer, Integration and Automation News →
📈 Atomwise Financials, Fundraising and Valuation News →
🛍️ Atomwise Product and Pricing News
- Atomwise uses deep learning to predict binding affinity between drug candidates and target proteins for diseases like leukaemia and Ebola.
👔 Atomwise CEO, Management and Leadership Team
-
Chief Executive Officer
[email protected]
⚔️ Atomwise Alternatives and Competitors
- Brightseed |
- Noetik |
- Oncocross |
- Exscientia |
- Terray Therapeutics |
- ZebiAI |
- Repurpose.AI |
- Xbiome |
- Accutar Biotech |
- ABEJA |
- Espressive |
- Vlex |
- Cardiologs |
- Schrödinger |
- InCrowd |
- DrugPatentWatch
💼 Atomwise Hiring and Layoffs
- Atomwise is currently seeking a Director/Senior Director of Project Management in the United States.
- Atomwise is hiring for remote positions including a Machine Learning Research Scientist/Engineer and a Cheminformatician for their drug discovery platform.
🤖 Atomwise Developer, Integration and Automation News
- Atomwise collaborated with Thoth Biosimulations to develop novel inhibitors for RMT1 that target hTERT-overexpressing cancer cells.
📈 Atomwise Financials, Fundraising and Valuation News
- Atomwise is identified as a key player in the AI-generated enzymes market, which is projected to reach USD 19,407.75 million by 2034.
People also viewed
